SCHEMBL8360732

SCHEMBL8360732

CN1C(=O)CN(Cc2ccccc2Cl)C1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.55
DRD3 P35462 1/20 0.55
KCNH2 Q12809 1/20 0.55
CYP1A2 P05177 2/20 0.51
CYP2C19 P33261 2/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 2/20 0.50
P2RX7 Q99572 2/20 0.47
TP53 P04637 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.45
POLB P06746 1/20 0.44
MAOB P27338 1/20 0.44
ADORA2A P29274 1/20 0.44
TRPC5 Q9UL62 1/20 0.43
TSHR P16473 1/20 0.43
CYP2C9 P11712 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8360735 0.82 ACHE (0.50) ALDH1A1P2RX7POLBMAOBADORA2A
SCHEMBL8363890 0.81 ALDH1A1 (0.51) CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1
SCHEMBL7212064 0.80 ENPP2 (0.53) DRD3KCNH2CYP2C19CYP3A4CYP2D6
SCHEMBL8633466 0.74 CYP1A2 (0.50) DRD2DRD3KCNH2CYP1A2CYP2C19
SCHEMBL4523295 0.73 CYP1A2 (0.64) DRD2DRD3KCNH2CYP1A2CYP2C19
SCHEMBL8360734 0.73 CYP2C9 (0.55) DRD2DRD3KCNH2CYP1A2CYP2C19
SCHEMBL838675 0.71 ENPP2 (0.43) MEN1KMT2A
SCHEMBL27048512 0.71 HTT (0.50) DRD2DRD3KCNH2CYP1A2CYP2C19
SCHEMBL3415753 0.70 MEN1 (0.56) DRD2DRD3KCNH2CYP1A2CYP2C19
SCHEMBL4133922 0.70 DRD2 (0.49) DRD2DRD3KCNH2CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054467-A1 Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases BETSCHART CLAUDIA 2009-02-26 US disclosed
US-20090054467-A1 Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases BETSCHART CLAUDIA 2009-02-26 US disclosed
US-7452886-B2 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases NOVARTIS AG (CH) 2008-11-18 US disclosed
US-7452886-B2 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases NOVARTIS AG (CH) 2008-11-18 US disclosed
WO-2003020721-A1 PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES NOVARTIS AG (CH) 2003-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054467-A1 Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases CTSK, CTSS, CTSZ DRD2 4870/4885DRD3 4862/4885KCNH2 4385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.